World Journal of Diabetes

World Journal of Diabetes is a monthly online open access journal published by Baishideng Publishing Group that covers clinical, basic and translational diabetes research, and it recorded a 2025 Journal Impact Factor of 5.1.《世界糖尿病杂志》（World Journal of Diabetes）是（Baishideng Publishing Group）出版的月刊在线开放获取期刊，刊载糖尿病的临床、基础与转化研究，2025 年期刊影响因子为 5.1。

Scope

• The journal covers risk factors for diabetes and the main clinical forms, namely type 1, type 2, gestational and experimental diabetes and the prediabetic state.本刊涵盖糖尿病的危险因素与主要临床类型，即 1 型、2 型、妊娠期与实验性糖尿病以及糖尿病前期状态。
• Complications in scope include diabetic angiopathies, cardiomyopathies, nephropathies, neuropathies, diabetic coma and diabetic ketoacidosis.收稿范围中的并发症包括糖尿病血管病、心肌病、肾病、神经病、糖尿病昏迷与糖尿病酮症酸中毒。
• Rare presentations such as Donohue syndrome and fetal macrosomia are also within the journal's remit.（Donohue）综合征与巨大胎儿等少见情况同样属于刊物范围。
• Article types include editorial, opinion review, frontier, review, minireview, clinical research, basic study, systematic review, meta-analysis, evidence-based medicine, field of vision, clinical guidelines, letter to the editor and case report.文章类型包括社论、观点评论、前沿、综述、小型综述、临床研究、基础研究、系统评价、荟萃分析、循证医学、视野、临床指南、致编辑信与病例报告。
• Authors are directed to the STROBE, CONSORT 2010, PRISMA 2009 and CARE reporting standards, and human, transplant and animal studies need formal ethics approval documents.作者须遵循（STROBE）、（CONSORT 2010）、（PRISMA 2009）与（CARE）报告规范，涉及人体、移植与动物研究时需提供正式伦理批准文件。
• Solicited and unsolicited manuscripts are both accepted, and the stated aim is a platform for high-quality clinical, basic and translational work.刊物同时接受约稿与自由来稿，其宗旨是搭建高质量临床、基础与转化研究的平台。

History

• The journal launched on 15 June 2010 and has published monthly since then under the DOI prefix 10.4239.本刊于 2010 年 6 月 15 日创刊，此后按月出版，使用（DOI）前缀 10.4239。
• It is issued by Baishideng Publishing Group, which was founded in 1993 and is headquartered in Pleasanton, California.本刊由百世登出版集团出版，该集团成立于 1993 年，总部位于加利福尼亚州普莱森顿。
• Publication is online only, with the single ISSN 1948-9358, and all content is free to read immediately.刊物仅在线出版，唯一（ISSN）为 1948-9358，全部内容可立即免费阅读。
• It is abstracted in Science Citation Index Expanded, Current Contents and the Journal Citation Reports, and in PubMed, PubMed Central and Reference Citation Analysis.本刊被（Science Citation Index Expanded）、（Current Contents）与《期刊引证报告》收录，并被（PubMed）、（PubMed Central）与（Reference Citation Analysis）索引。
• The Journal Impact Factor rose from 3.763 in 2021 and 4.56 in 2022 to 4.6 in 2024 and 5.1 in 2025, ranking 46th of 198 titles at the 77.0th percentile.期刊影响因子从 2021 年的 3.763、2022 年的 4.56 升至 2024 年的 4.6 与 2025 年的 5.1，在 198 种期刊中列第 46 位，百分位为 77.0。
• Recent manuscript statistics report 407 submissions, a mean first decision time of 40 days, an acceptance rate of 24.1 percent and a mean time to publication of 162 days.近期稿件统计显示来稿 407 篇，首次决定平均 40 天，录用率 24.1%，平均发表周期 162 天。

Editors

• The editors-in-chief, for the term from 1 April 2025 to 31 December 2028, are Lu Cai of the University of Louisville, Michael Horowitz of the Royal Adelaide Hospital and Md. Shahidul Islam of the University of KwaZulu-Natal.2025 年 4 月 1 日至 2028 年 12 月 31 日任期内，主编为路易斯维尔大学的（Lu Cai）、皇家阿德莱德医院的（Michael Horowitz）与夸祖鲁-纳塔尔大学的（Md. Shahidul Islam）。
• The associate editors are Alessandra Fierabracci of Bambino Gesu Children's Hospital in Rome, Chii-Min Hwu of Taipei Veterans General Hospital and Joseph M Pappachan of Manchester Metropolitan University and Lancashire Teaching Hospitals.副编辑为罗马耶稣圣婴儿童医院的（Alessandra Fierabracci）、台北荣民总医院的（Chii-Min Hwu）以及曼彻斯特城市大学与兰开夏教学医院的（Joseph M Pappachan）。
• The editorial board has 47 members from 19 countries and regions, led by China with 17, the United States with 4, and India, Spain and Turkiye with 3 each.编委会有 47 位成员，来自 19 个国家与地区，其中中国 17 位、美国 4 位，印度、西班牙与土耳其各 3 位。
• Every paper undergoes external single-blind peer review, and acceptance depends on novelty, data accuracy, image reliability, language clarity and ethical requirements.所有稿件均经过外部单盲同行评审，录用取决于新颖性、数据准确性、图像可靠性、语言清晰度与伦理要求。
• Designation of co-first authors and co-corresponding authors is permitted when the contributions are equal.贡献相同时允许标注共同第一作者与共同通讯作者。
• Peer review reports, author responses, biostatistics certificates, ethics approvals, CrossCheck reports and copyright agreements are published alongside each article.同行评审报告、作者答复、生物统计证明、伦理批准、（CrossCheck）报告与版权协议随每篇文章一同发表。